BRPI0510394A - inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 - Google Patents

inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1

Info

Publication number
BRPI0510394A
BRPI0510394A BRPI0510394-0A BRPI0510394A BRPI0510394A BR PI0510394 A BRPI0510394 A BR PI0510394A BR PI0510394 A BRPI0510394 A BR PI0510394A BR PI0510394 A BRPI0510394 A BR PI0510394A
Authority
BR
Brazil
Prior art keywords
hydroxysteroid dehydrogenase
inhibitors
beta
compounds
dehydrogenase type
Prior art date
Application number
BRPI0510394-0A
Other languages
English (en)
Inventor
Martin Henriksson
Evert Homan
Lars Johansson
Jerk Vallgarda
Meredith Williams
Eric Bercot
Christopher H Fotsch
Aiwen Li
Guolin Cai
Randall W Hungate
Original Assignee
Amgen Inc
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0401324A external-priority patent/SE0401324D0/xx
Priority claimed from SE0402509A external-priority patent/SE0402509D0/xx
Application filed by Amgen Inc, Biovitrum Ab filed Critical Amgen Inc
Publication of BRPI0510394A publication Critical patent/BRPI0510394A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

INIBIDORES DE 11-BETA-HIDROXIESTERóIDE DESIDROGENASE TIPO 1. A presente invenção refere-se a compostos com as fórmula (I), (II), (III) ou (IV): em que R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬, X e Z são como aqui definido, e também à composições farmacêuticas que compreendem os compostos, bem como métodos de uso dos compostos para tratamento de distúrbios associados com a enzima 11-<225>- hidroxiesteróide desidrogenase humana tipo 1 e para a preparação de um medicamento que age sobre a enzima 11-<225>-hidroxiesteróide desidrogenase humana tipo 1.
BRPI0510394-0A 2004-05-24 2005-05-24 inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 BRPI0510394A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0401324A SE0401324D0 (sv) 2004-05-24 2004-05-24 New compounds
SE0402509A SE0402509D0 (sv) 2004-10-15 2004-10-15 New compounds
US65077705P 2005-01-31 2005-01-31
PCT/US2005/018081 WO2005116002A2 (en) 2004-05-24 2005-05-24 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Publications (1)

Publication Number Publication Date
BRPI0510394A true BRPI0510394A (pt) 2007-11-13

Family

ID=35134299

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510394-0A BRPI0510394A (pt) 2004-05-24 2005-05-24 inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1

Country Status (16)

Country Link
US (4) US7253196B2 (pt)
EP (1) EP1753736B1 (pt)
JP (1) JP4789934B2 (pt)
CN (1) CN1964956B (pt)
AR (1) AR049344A1 (pt)
AT (1) ATE417837T1 (pt)
AU (1) AU2005247929B2 (pt)
BR (1) BRPI0510394A (pt)
CA (1) CA2568186C (pt)
DE (1) DE602005011795D1 (pt)
EA (1) EA014419B1 (pt)
ES (1) ES2318503T3 (pt)
GE (1) GEP20094666B (pt)
MY (1) MY148480A (pt)
TW (1) TWI352700B (pt)
WO (1) WO2005116002A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
AR049344A1 (es) * 2004-05-24 2006-07-19 Amgen Inc Inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa de tipo 1
US8686011B2 (en) * 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP2835367A1 (en) 2005-01-05 2015-02-11 AbbVie Inc. Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101496206B1 (ko) 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7563813B2 (en) 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
CA2610196A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP1951696A2 (en) * 2005-11-22 2008-08-06 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE602006011360D1 (de) 2005-11-22 2010-02-04 Amgen Inc Katalysiertes verfahren zur herstellung von c-5-substituierten heterocyclischen inhibitoren von 11beta-hydroxysteroiddehydrogenase vom typ 1
BRPI0710479A2 (pt) 2006-01-18 2012-08-14 Hoffmann La Roche composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8927715B2 (en) 2006-08-25 2015-01-06 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US20110150825A1 (en) * 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
CA2686651C (en) * 2007-05-25 2015-11-24 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2008156601A1 (en) * 2007-06-14 2008-12-24 Amgen Inc. Tricyclic inhibitors of hydroxysteroid dehydrogenases
CA2692128A1 (en) * 2007-06-21 2008-12-31 Amgen Inc. Process for making substituted 2-amino-thiazolones
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
WO2009038064A1 (ja) * 2007-09-19 2009-03-26 Institute Of Medicinal Molecular Design, Inc. Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
PL2300461T3 (pl) 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
BRPI0915177A2 (pt) * 2008-06-20 2016-04-26 Amgen Inc processo para fazer 2-amino-tiazolonas substituídas
EP2687525B1 (en) 2008-07-25 2015-09-23 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
PL2321290T3 (pl) * 2008-07-29 2012-11-30 Amgen Inc Asymetryczny proces wytwarzania podstawionych 2-aminotiazolonów
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
JP5750449B2 (ja) 2009-11-05 2015-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規キラルリンリガンド
US8648192B2 (en) 2010-05-26 2014-02-11 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
BR112013005434A2 (pt) 2010-09-23 2016-06-07 Abbott Lab novo mono-hidrato de derivados de aza-adamantano
US20130310431A1 (en) * 2010-10-15 2013-11-21 Amgen Inc Uses for substituted 2-amino-thiazolones in treating alzheimer's disease
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CN102408392A (zh) * 2011-11-10 2012-04-11 浙江大学 水相中2-(n, n-二取代氨基)-4-噻唑啉酮的绿色制备方法
RU2483722C1 (ru) * 2012-05-22 2013-06-10 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Аминотиазольные производные усниновой кислоты как новые противотуберкулезные агенты
JP6612874B2 (ja) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物
KR20180044256A (ko) 2015-06-10 2018-05-02 엑소반트 사이언시즈 게엠베하 A7-니코틴성 아세틸콜린 수용체의 작용제로서의 아미노벤즈이소옥사졸 화합물
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
JP7493835B2 (ja) * 2019-11-06 2024-06-03 アルベルト・アインシュタイン・カレッジ・オブ・メディシン 小分子プロスタグラジン輸送阻害剤
CN115322208B (zh) * 2021-05-10 2023-04-11 中国药科大学 2-氨基噻唑类衍生物及其制备方法和医药用途
CN115010616B (zh) * 2022-07-01 2024-03-26 常州锐博生物科技有限公司 一种1-氨基环丙烷羧酸盐酸盐的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786838A (en) * 1957-03-26 Cshy b
US2701248A (en) * 1950-12-30 1955-02-01 Monsanto Chemicals Esters of pseudothiohydantoin-5-acetic acid and method for their preparation
DE929549C (de) * 1951-11-29 1955-08-01 Hoechst Ag Verfahren zur Herstellung substituierter Pseudothiohydantoine und ihrer Hydrohalogenide
FR6278M (pt) * 1966-12-14 1968-09-02
US4428948A (en) * 1977-02-03 1984-01-31 Rohm And Haas Company Novel heterocyclic compounds
JPS58183603A (ja) * 1982-04-19 1983-10-26 Mitsubishi Chem Ind Ltd 土壌病害用殺菌剤
ZA844557B (en) * 1983-06-23 1985-02-27 Hoffmann La Roche Novel thiazolidine derivatives
DK277484A (da) * 1983-06-23 1984-12-24 Hoffmann La Roche Thiazolidinderivater
JPH08277266A (ja) * 1983-09-14 1996-10-22 Alcon Lab スピロ三環式芳香族スクシンイミド誘導体、並びにヒト及び動物の糖尿病合併症治療剤
JPS6360987A (ja) * 1986-08-29 1988-03-17 Tanabe Seiyaku Co Ltd キナゾリノン誘導体の製法
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
KR20000005291A (ko) * 1996-06-25 2000-01-25 다케다 야쿠힌 고교 가부시키가이샤 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
BR0214344A (pt) 2001-11-22 2004-09-14 Biovitrum Ab Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE469136T1 (de) 2001-11-22 2010-06-15 Biovitrum Ab Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
SE0301882D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301883D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use II
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301888D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
SE0301884D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use III
SE0301885D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use IV
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
US20050239853A1 (en) * 2004-02-04 2005-10-27 Tjeerd Barf New compounds
AR049344A1 (es) * 2004-05-24 2006-07-19 Amgen Inc Inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa de tipo 1

Also Published As

Publication number Publication date
US20110082107A1 (en) 2011-04-07
CN1964956B (zh) 2013-03-27
US20070281938A1 (en) 2007-12-06
ES2318503T3 (es) 2009-05-01
JP2008500353A (ja) 2008-01-10
TW200609227A (en) 2006-03-16
US20080045503A1 (en) 2008-02-21
DE602005011795D1 (de) 2009-01-29
EP1753736B1 (en) 2008-12-17
JP4789934B2 (ja) 2011-10-12
AR049344A1 (es) 2006-07-19
EP1753736A2 (en) 2007-02-21
US20060142357A1 (en) 2006-06-29
TWI352700B (en) 2011-11-21
US7253196B2 (en) 2007-08-07
CA2568186A1 (en) 2005-12-08
EA200602191A1 (ru) 2007-06-29
MY148480A (en) 2013-04-30
AU2005247929B2 (en) 2010-03-11
GEP20094666B (en) 2009-04-10
WO2005116002B1 (en) 2006-08-24
EA014419B1 (ru) 2010-12-30
CA2568186C (en) 2011-11-15
CN1964956A (zh) 2007-05-16
WO2005116002A2 (en) 2005-12-08
WO2005116002A3 (en) 2006-07-06
US7807700B2 (en) 2010-10-05
AU2005247929A1 (en) 2005-12-08
ATE417837T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
BR0214342A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0214344A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
BRPI0611863A2 (pt) composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BR0214386A (pt) Método para identificação de enzimas de objetivação a tumor
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0413695A (pt) derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
BR0013248A (pt) Inibidores da adesão celular
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
ECSP088839A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
BRPI0511531A (pt) composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2309 DE 07/04/2015.